Wolinsky JS - Search Results

1

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. Among authors: wolinsky js. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.

2

Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients.

Kerman RH, Wolinsky JS, Nath A, Sears ES Jr. Kerman RH, et al. Among authors: wolinsky js. J Neuroimmunol. 1988 Jul;18(4):325-31. doi: 10.1016/0165-5728(88)90053-7. J Neuroimmunol. 1988. PMID: 2968363 Clinical Trial.

3

Multiple sclerosis: clinical presentation, diagnosis and treatment.

Brod SA, Lindsey JW, Wolinsky JS. Brod SA, et al. Among authors: wolinsky js. Am Fam Physician. 1996 Sep 15;54(4):1301-6, 1309-11. Am Fam Physician. 1996. PMID: 8816574 Review.

4

Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.

Brod SA, Kerman RH, Nelson LD, Marshall GD Jr, Henninger EM, Khan M, Jin R, Wolinsky JS. Brod SA, et al. Among authors: wolinsky js. Mult Scler. 1997 Feb;3(1):1-7. doi: 10.1177/135245859700300101. Mult Scler. 1997. PMID: 9160341 Clinical Trial.

5

The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis.

Arnold DL, Wolinsky JS, Matthews PM, Falini A. Arnold DL, et al. Among authors: wolinsky js. J Neurol Neurosurg Psychiatry. 1998 May;64 Suppl 1:S94-101. J Neurol Neurosurg Psychiatry. 1998. PMID: 9647294 Free article. Review.

6

Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis.

Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL. Matthews PM, et al. Among authors: wolinsky js. Semin Neurol. 1998;18(3):327-36. doi: 10.1055/s-2008-1040884. Semin Neurol. 1998. PMID: 9817537 Review.

7

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS, et al. Mult Scler. 2001 Feb;7(1):33-41. doi: 10.1177/135245850100700107. Mult Scler. 2001. PMID: 11321192 Clinical Trial.

8

MRI aspects of secondary progressive multiple sclerosis.

Wolinsky JS. Wolinsky JS. Mult Scler. 2002 Feb;8(1):85-7. doi: 10.1177/135245850200800118. Mult Scler. 2002. PMID: 11936494 Review. No abstract available.

9

Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group.

Filippi M, Falini A, Arnold DL, Fazekas F, Gonen O, Simon JH, Dousset V, Savoiardo M, Wolinsky JS; White Matter Study Group. Filippi M, et al. Among authors: wolinsky js. J Magn Reson Imaging. 2005 Jun;21(6):669-75. doi: 10.1002/jmri.20336. J Magn Reson Imaging. 2005. PMID: 15906322 Review.

10

Disease management in multiple sclerosis.

Bates D, Toyka KV, Wolinsky JS, Arnold D. Bates D, et al. Among authors: wolinsky js. Eur Neurol. 2005;53(4):203-5. doi: 10.1159/000086480. Epub 2005 Apr 21. Eur Neurol. 2005. PMID: 15976505 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters